NCT00477971View on ClinicalTrials.gov

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2012

Study Completion Date

December 31, 2014

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

filgrastim

No administration information given

DRUG

dexamethasone

Given orally

DRUG

melphalan

Given IV or orally

PROCEDURE

autologous hematopoietic stem cell transplantation

Given on day 0

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER